Found: 47
Select item for more details and to access through your institution.
Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 5, p. 1002, doi. 10.3390/jcm10051002
- By:
- Publication type:
- Article
Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial.
- Published in:
- Hematology Reviews, 2009, v. 1, n. 2, p. 62, doi. 10.4081/hr.2009.e11
- By:
- Publication type:
- Article
Response to: Interference of daratumumab on the serum protein electrophoresis.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2017, v. 55, n. 2, p. e29, doi. 10.1515/cclm-2016-1026
- By:
- Publication type:
- Article
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 6, p. 1095, doi. 10.1515/cclm-2015-1031
- By:
- Publication type:
- Article
Patient pools and the use of "patient means" are valuable tools in quality control illustrated by a bone-specific alkaline phosphatase assay.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 3, p. 403, doi. 10.1515/cclm-2015-0308
- By:
- Publication type:
- Article
Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
- Published in:
- Journal of Bone & Mineral Research, 2013, v. 28, n. 8, p. 1738, doi. 10.1002/jbmr.1897
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
- By:
- Publication type:
- Article
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 6, p. 1105, doi. 10.1111/bjh.17302
- By:
- Publication type:
- Article
"Fine‐tuning cytoreduction in resistant multiple myeloma ‐ progress here, too"?
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 275, doi. 10.1111/bjh.16061
- By:
- Publication type:
- Article
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 3, p. e35, doi. 10.1111/bjh.15879
- By:
- Publication type:
- Article
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 1, p. 61, doi. 10.1111/bjh.14637
- By:
- Publication type:
- Article
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 6, p. 876, doi. 10.1111/bjh.14138
- By:
- Publication type:
- Article
High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 3, p. 355, doi. 10.1111/bjh.13584
- By:
- Publication type:
- Article
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 3, p. 393, doi. 10.1111/bjh.12541
- By:
- Publication type:
- Article
Daratumumab for the Treatment of Multiple Myeloma.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.01228
- By:
- Publication type:
- Article
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
- Published in:
- Drugs, 2016, v. 76, n. 9, p. 989, doi. 10.1007/s40265-016-0590-3
- By:
- Publication type:
- Article
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
- Published in:
- Drugs, 2016, v. 76, n. 8, p. 853, doi. 10.1007/s40265-016-0573-4
- By:
- Publication type:
- Article
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
- Published in:
- Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
- By:
- Publication type:
- Article
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
- Published in:
- European Journal of Haematology, 2010, v. 85, n. 4, p. 290, doi. 10.1111/j.1600-0609.2010.01485.x
- By:
- Publication type:
- Article
Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 5, p. 412, doi. 10.1111/j.1600-0609.2010.01417.x
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e281, doi. 10.1016/j.clml.2019.09.463
- By:
- Publication type:
- Article
European Post-Authorization Safety Study of Patients With Relapsed or Refractory Multiple Myeloma Treated With Pomalidomide in a Real-World Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e256, doi. 10.1016/j.clml.2019.09.423
- By:
- Publication type:
- Article
Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e225, doi. 10.1016/j.clml.2019.09.375
- By:
- Publication type:
- Article
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.113
- By:
- Publication type:
- Article
The Danish National Multiple Myeloma Registry.
- Published in:
- Clinical Epidemiology, 2016, v. 8, p. 583, doi. 10.2147/CLEP.S99463
- By:
- Publication type:
- Article
Preface.
- Published in:
- European Journal of Haematology, 1990, v. 45, n. S53, p. 1, doi. 10.1111/j.1600-0609.1990.tb01517.x
- By:
- Publication type:
- Article
Lack of prognostic significance of T-lymphocyte subset counts in B-cell chronic lyrnphocytic leukaemia.
- Published in:
- European Journal of Haematology, 1987, v. 38, n. 1, p. 67, doi. 10.1111/j.1600-0609.1987.tb01427.x
- By:
- Publication type:
- Article
Clinically‐suspected cast nephropathy: A retrospective, national, real‐world study.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1352, doi. 10.1002/ajh.25959
- By:
- Publication type:
- Article
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
- Published in:
- American Journal of Hematology, 2005, v. 78, n. 4, p. 275
- By:
- Publication type:
- Article
Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 21, p. 3365, doi. 10.3390/cells11213365
- By:
- Publication type:
- Article
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 2, p. 378, doi. 10.3390/cells9020378
- By:
- Publication type:
- Article
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
- Published in:
- Acta Oncologica, 2014, v. 53, n. 4, p. 547, doi. 10.3109/0284186X.2013.844358
- By:
- Publication type:
- Article
Monoclonal Antibodies in Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2015, v. 13, n. 9, p. 599
- By:
- Publication type:
- Article
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 5, p. 714, doi. 10.1111/bjh.12154
- By:
- Publication type:
- Article
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 4, p. 551, doi. 10.1111/j.1365-2141.2009.07980.x
- By:
- Publication type:
- Article
European Perspective on Multiple Myeloma Treatment Strategies in 2014.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
European Perspective on Multiple Myeloma Treatment Strategies in 2014.
- Published in:
- Oncologist, 2014, v. 19, n. 8, p. 829, doi. 10.1634/theoncologist.2014-0042
- By:
- Publication type:
- Article
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective.
- Published in:
- Oncologist, 2011, v. 16, n. 4, p. 388, doi. 10.1634/theoncologist.2010-0386
- By:
- Publication type:
- Article
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective.
- Published in:
- Oncologist, 2010, v. 15, n. 1, p. 6, doi. 10.1634/theoncologist.2009-0203
- By:
- Publication type:
- Article
Immunochemical Studies of Human β<sub>2</sub>-Microglobulin.
- Published in:
- Allergy, 1980, v. 35, n. 8, p. 627, doi. 10.1111/j.1398-9995.1980.tb02015.x
- By:
- Publication type:
- Article
The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
- Published in:
- British Journal of Haematology, 1995, v. 89, n. 3, p. 576, doi. 10.1111/j.1365-2141.1995.tb08366.x
- By:
- Publication type:
- Article